Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clément Hoguin

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of the American Society of Nephrology : JASN|June 3, 2021
REST and Stress Resistance in the Aging KidneySato Magassa, Liviu Aron, Clément Hoguin, et al.
PNAS Nexus|June 1, 2026
Oncogenic PIK3CA mutations shape an immunoregulatory microenvironment in mosaic overgrowth disordersIlaria Galasso, Charles Bayard, Camille Blériot, et al.
The Journal of Experimental Medicine|January 26, 2022
Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisibGabriel Morin, Caroline Degrugillier-Chopinet, Marie Vincent, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 2025
<i>PIK3CA</i> gain-of-function mutation in Schwann cells leads to severe neuropathy and aerobic glycolysis through a non-cell autonomous effectQuitterie Venot, Marina Firpion, Sophia Ladraa, et al.
The New England Journal of Medicine|July 17, 2024
Sotorasib for Vascular Malformations Associated with <i>KRAS</i> G12C MutationAntoine Fraissenon, Charles Bayard, Gabriel Morin, et al.
The Journal of Clinical Investigation|June 6, 2024
PIK3CA inhibition in models of proliferative glomerulonephritis and lupus nephritisJunna Yamaguchi, Pierre Isnard, Noémie Robil, et al.
Science Translational Medicine|October 6, 2021
Alpelisib administration reduced lymphatic malformations in a mouse model and in patientsFlorence Delestre, Quitterie Venot, Charles Bayard, et al.
The Journal of Experimental Medicine|September 15, 2023
Hemifacial myohyperplasia is due to somatic muscular PIK3CA gain-of-function mutations and responds to pharmacological inhibitionCharles Bayard, Eleonora Segna, Maxime Taverne, et al.
Signal Transduction and Targeted Therapy|June 16, 2024
Targeted therapy for capillary-venous malformationsLola Zerbib, Sophia Ladraa, Antoine Fraissenon, et al.
Science Advances|December 9, 2022
PIK3CA gain-of-function mutation in adipose tissue induces metabolic reprogramming with Warburg-like effect and severe endocrine disruptionSophia Ladraa, Lola Zerbib, Charles Bayard, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of the American Society of Nephrology : JASN|June 3, 2021
REST and Stress Resistance in the Aging KidneySato Magassa, Liviu Aron, Clément Hoguin, et al.
PNAS Nexus|June 1, 2026
Oncogenic PIK3CA mutations shape an immunoregulatory microenvironment in mosaic overgrowth disordersIlaria Galasso, Charles Bayard, Camille Blériot, et al.
The Journal of Experimental Medicine|January 26, 2022
Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisibGabriel Morin, Caroline Degrugillier-Chopinet, Marie Vincent, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 2025
<i>PIK3CA</i> gain-of-function mutation in Schwann cells leads to severe neuropathy and aerobic glycolysis through a non-cell autonomous effectQuitterie Venot, Marina Firpion, Sophia Ladraa, et al.
The New England Journal of Medicine|July 17, 2024
Sotorasib for Vascular Malformations Associated with <i>KRAS</i> G12C MutationAntoine Fraissenon, Charles Bayard, Gabriel Morin, et al.
The Journal of Clinical Investigation|June 6, 2024
PIK3CA inhibition in models of proliferative glomerulonephritis and lupus nephritisJunna Yamaguchi, Pierre Isnard, Noémie Robil, et al.
Science Translational Medicine|October 6, 2021
Alpelisib administration reduced lymphatic malformations in a mouse model and in patientsFlorence Delestre, Quitterie Venot, Charles Bayard, et al.
The Journal of Experimental Medicine|September 15, 2023
Hemifacial myohyperplasia is due to somatic muscular PIK3CA gain-of-function mutations and responds to pharmacological inhibitionCharles Bayard, Eleonora Segna, Maxime Taverne, et al.
Signal Transduction and Targeted Therapy|June 16, 2024
Targeted therapy for capillary-venous malformationsLola Zerbib, Sophia Ladraa, Antoine Fraissenon, et al.
Science Advances|December 9, 2022
PIK3CA gain-of-function mutation in adipose tissue induces metabolic reprogramming with Warburg-like effect and severe endocrine disruptionSophia Ladraa, Lola Zerbib, Charles Bayard, et al.
Pageof 2